myTomorrows, a Dutch HealthTech firm that connects sufferers with attainable pre-approval remedies, at present introduced the shut of a €25 million financing to be able to speed up the worldwide growth of its AI-driven platform and improve entry to rising therapies for sufferers worldwide.
Avego’s development fairness funding will gasoline the worldwide growth of myTomorrows’ built-in pharma options to make rising remedies extra equitable and accessible for sufferers globally.
“This funding marks a pivotal step in our journey to provide each affected person, regardless of the place they reside, a good shot at tomorrow’s therapies,” stated Michel van Harten, CEO of myTomorrows. “Avego’s intensive experience in life sciences, notably BioPharma, will probably be instrumental as we scale our platform and broaden our impression throughout the worldwide well being panorama.”
This growth-equity funding in myTomorrows aligns with a number of notable 2025 European HealthTech funding rounds.
In Belgium, Sequana Medical secured €24 million to assist the US launch of its “alfapump” system for continual fluid-retention administration. In France, ArcaScience raised €6 million to boost AI-driven benefit-risk intelligence for drug improvement. In the meantime, Finland’s CurifyLabs obtained €6.7 million to modernise the manufacturing of personalised medicines.
Whereas these firms function in adjoining segments of the broader HealthTech and BioPharma panorama, myTomorrows stands out for its deal with affected person entry to pre-approval therapies by an AI-enabled platform that connects physicians, trial websites, and biopharma companions.
Its spherical represents one of many extra substantial Dutch HealthTech financings reported in 2025, underlining continued investor confidence in expertise options that bridge early-stage drug improvement and affected person entry.
Ronald Brus, Founder and Board Member of myTomorrows, added: “Once we based myTomorrows in 2012, we envisioned a greater approach to join sufferers with promising therapies – one that enhances drug improvement and expands entry to innovation. This funding marks the start of a subsequent part of accelerated development and worldwide impression.”
Based in 2012, myTomorrows is a worldwide HealthTech firm that connects sufferers, physicians, trial websites, and BioPharma companions to allow earlier and higher entry to pre-approval remedies.
By way of a centralised, multi-stakeholder platform, myTomorrows combines AI-driven insights with human experience to ship tailor-made options that purpose to beat a few of at present’s best obstacles to affected person entry.
Headquartered in Amsterdam, with an workplace in New York Metropolis, myTomorrows has supported greater than 16,900 sufferers and a pair of,800 physicians throughout 340+ websites in over 133 international locations.
With greater than 300 million sufferers worldwide going through circumstances with out permitted remedy choices, and over 10,000 therapies at the moment in improvement or awaiting approval – myTomorrows is addressing one in all healthcare’s most pressing challenges: bridging the hole between scientific development and affected person entry to pre-approval remedies, which embrace medical trials and expanded entry packages (EAPs).
The brand new funding will speed up myTomorrows’ worldwide development and additional develop its AI-driven international platform that connects physicians and their sufferers, trial websites and BioPharma companions to streamline entry and perception.
It should additionally strengthen collaborations with trade companions to shorten medical improvement timelines and improve real-world information capabilities, supporting proof technology and regulatory perception.
“Avego is proud to assist myTomorrows in its mission to remodel how sufferers and physicians entry therapies in improvement,” stated James Flexner, Managing Companion at Avego. “We consider myTomorrows is uniquely positioned to take away obstacles for sufferers and suppliers whereas serving as a vital associate to BioPharma.”
For BioPharma companions, myTomorrows offers medical trial recruitment, expanded entry options, and real-world information assortment. For trial websites, the platform gives a unified referral administration system that enhances trial visibility and permits real-time standing updates.
EU-Startups has featured myTomorrows a number of occasions – first in 2017, reporting on its €10 million funding spherical, and later in its 2021 roundup of high healthcare startups within the Netherlands.
